The detection of small and low abundant biomarkers in clinical samples remains a challenge, mainly due to the presence of high-abundant proteins, such as albumin (HSA) and immunoglobulin G (IgG), accounting for at least 65% of plasma proteins. 1 The depletion of these proteins could facilitate biomarker discovery and detection. Depletion should aim to provide the selective removal of high-abundant proteins, and concentrate components of low abundance. Commercially available methods for IgG and HSA depletion have enabled the visualization of new protein signals, the identification of gene products and improved detection of low-abundant proteins. [2] [3] [4] Most of the methods utilize either antibody-or dye-based resins, 3,5 molecular size filtration, organic solvents, and ammonium sulfate precipitation, as well as reverse phase and ion exchange chromatography. 5, 6 Also available are resins cross-linked with proteins A and G, and their recombinants for IgG removal. 3, 7 Antibody-based resins display higher specificity and efficiency, 4,8 but are more expensive than the dye-based resins, limiting their usage. Commercially available pre-packed columns lack the flexibility to accommodate issues pertaining to sample size, for example. In addition, some rely on use of pumps and other equipment to operate smoothly, 2, 3 thus limiting their use in many health centers. Most studies on IgG/HSA depletion have focused on the detection of lowabundant proteins using electrophoresis and mass spectrometry.
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The depletion of these proteins could facilitate biomarker discovery and detection. Depletion should aim to provide the selective removal of high-abundant proteins, and concentrate components of low abundance. Commercially available methods for IgG and HSA depletion have enabled the visualization of new protein signals, the identification of gene products and improved detection of low-abundant proteins. [2] [3] [4] Most of the methods utilize either antibody-or dye-based resins, 3 ,5 molecular size filtration, organic solvents, and ammonium sulfate precipitation, as well as reverse phase and ion exchange chromatography. 5, 6 Also available are resins cross-linked with proteins A and G, and their recombinants for IgG removal. 3, 7 Antibody-based resins display higher specificity and efficiency, 4, 8 but are more expensive than the dye-based resins, limiting their usage. Commercially available pre-packed columns lack the flexibility to accommodate issues pertaining to sample size, for example. In addition, some rely on use of pumps and other equipment to operate smoothly, 2, 3 thus limiting their use in many health centers. Most studies on IgG/HSA depletion have focused on the detection of lowabundant proteins using electrophoresis and mass spectrometry. 2, 3, 9 As far as we are aware, the effects of depletion on point-of-care-testing (POCT) immunochromatography membrane-based assays is yet to be reported. Further, an evaluation of the potential benefits of HSA depletion over IgG, and vice versa has received very little attention to date.
In this report, we present (a) a versatile method for HSA and IgG depletion from quality control (QC) and human serum samples, (b) assess the effect of depletion on human chorionic gonadotropin (HCG) and prostate specific antigen (PSA) using immunochromatography test strips (ICTS), and (c) evaluate the effects of HSA depletion compared to that of IgG on HCG and PSA detection. We employed a dye-based removal of HSA using Cibacron Blue 3G-A Sepharose (SB). SB has a strong affinity towards HSA. 10 For the removal of IgG, we exploited the high affinity between the Fc region of antibodies and protein G using sepharose beads cross-linked with protein G (S-PG). 7 
Experimental

Materials
SB and S-PG were purchased from GE Healthcare BioSciences AB (Uppsala, Sweden). Handee TM spin columns (500 μL) and IgG specific kit (Easy-Titre ® IgG assay kit) were purchased from Pierce (IL, USA). HSA blue fluorescent assay kit was from Active Motif Japan (Tokyo, Japan). Prostate specific antigen (PSA) was obtained from Chemicon International (Temecula, CA, USA). Unless otherwise stated, all other reagents were from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). All solutions were prepared and diluted using ultra-pure water (18.3 MΩ cm -1 ) from the Millipore Milli-Q system.
Procedure
First, we transferred aliquots of S-PG, to Handee TM spin columns (500 μL, Pierce), and removed ethanol by centrifugation at 8000g for 10 min. Following washing with buffer solution and centrifugation, we immediately added a fresh buffer solution for equilibration. An IgG QC sample (10 mg/mL) was subsequently added to the swollen beads at IgG:S-PG ratios of 1:4, 1:2, 1:1, in order to establish an optimal binding ratio, and incubated for 1 h with continual shaking. Thereafter, the samples were centrifuged; the supernatants were collected and stored at -20˚C until analysis. For studies with serum, we chose a 1:4 ratio for maximum depletion in case the presence of other We collected human blood samples in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 1996. The blood was transferred into a test tube and incubated for 3 h at 40˚C. Afterwards, it was aliquoted and centrifuged at 3000 rpm for 10 min and the supernatant was stored at -20˚C until use. For IgG removal, we followed the procedure outlined above. All reactions were performed at room temperature, and reagents were prepared in a 20 mM sodium phosphate buffer solution, pH 7. Using similar conditions, HSA depletion was carried out at HSA:SB ratios 1:6, 1:4, 1:2, because the HSA serum concentration is higher than that of IgG, 1 and the quoted binding capacities of SB and S-PG by the supplier, were comparable.
The HSA concentrations were determined using a HSA blue fluorescent assay kit (Active Motif Japan) according to the manufacturer's protocol.
In order to assess the effect of depletion on some lowabundant biomarkers, we chose immunochromatography membrane strips as our analytical tool, to complement on-going studies in our laboratory aimed at POCT. Initially, we used HCG, a well-studied molecule using ICTS. We carried out an ICTS assay 11 without the membrane-enhanced procedure, using treated (IgG-and HSA-depleted) and non-treated serum samples.
Results and Discussion
Depletion of immunoglobulins (IgG) and human serum albumin (HSA) from serum
The IgG concentration was determined using an IgG-specific kit. The assay procedure uses anti IgG antibodies-coated beads, which absorb light at 340 and 405 nm. We found the working range to be between 20 and 200 ng/mL of IgG. After the depletion of IgG from QC samples, the supernatant IgG concentrations in samples of IgG:S-PG (composition ratios 1:4, 1:2, 1:1) were not detectable, 6.1 and 32.4 μg/mL. This gave percent depletion values of 100, 99.9 and 99.7%, respectively. The concentration of IgG in serum samples was determined at 16.8 mg/mL, in agreement with a previous study. 7 After depletion, the IgG concentration was reduced to 3.5 μg/mL (∼99.9% depletion; RSD < 0.2%).
Using a HSA blue fluorescent assay kit, the standard curve of HSA was linear between 12.5 and 200 μg/mL.
The concentration of HSA in serum was determined at 47.5 mg/mL, in accordance with literature.
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Using QC samples, the concentration of HSA was reduced by 99.3, 97.0 and 89.3% from 1:6, 1:4 and 1:2, respectively. For HSA depletion from serum, we followed the same procedure as for IgG removal, using an HSA:SB ratio of 1:4. After depletion, HSA was reduced by 97.2% to a mean value of 1.26 μg/mL (n = 6; RSD < 0.8%).
A simplified one-step co-depletion method for IgG and HSA from serum
In order to simplify the depletion of these high-abundant proteins, we proceeded to deplete HSA, followed by IgG, from the same sample, determining the concentration of HSA after each step. The results show specificity of the binding process, i.e., no IgG was co-depleted with HSA. We simplified the process further by combining the two protocols into a single procedure, adding S-PG and SB to spin columns at protein:resin ratios of 1:4, and incubating as before. The supernatants were assayed for the IgG and HSA concentrations (Table 1 ). In addition, we investigated the effect of decreasing the incubation time from 60 to 15 min. The results showed no change and a negligible decrease of 0.8% in the depletion rate of IgG and HSA, respectively. We concluded that a 15-min incubation period is sufficient to deplete > 97% HSA and 99.9% IgG ( Table 1) .
Application of depletion protocol to detection of prostate specific antigen (PSA)
First, we determined the relationship between the HCG concentration and the color intensity of HCG on immunochromatography test strips (Fig. 1) . The limit of detection (LoD) for HCG in serum using ICTS, was previously reported at 0.5 ng/mL. 11 Following our depletion protocol, the HCG LoD was 0.25 ng/mL for QC standards, HSA-depleted and IgG-depleted samples, and 0.5 ng/mL for serum and serum depleted of both IgG and HSA. Figure 2 shows the color intensity of HCG test strips in the four samples at 2 and 0.5 ng/mL.
We applied this method to the detection of PSA, a biomarker for prostate cancer. PSA is a 34 kDa intracellular glycoprotein synthesized only by prostate glands. It is present in normal benign hyperplastic, malignant prostatic tissue and metastatic prostate casicoma. 12 In blood, PSA exists both as free PSA and as an antichymotrypsin complex. 13 Total PSA (TPSA) is the sum of the free form and a complexed form. The cut-off HSA depletion, % of control Sample a. Depletion of HSA followed by that of IgG from the same sample but using different columns. value of TPSA between prostate hyperplasia and cancer is 4 ng/mL. 14 Several detection kits for TPSA, based on immunochromatography, are commercially available 15, 16 and mostly target 4 ng/mL as the sensitivity level. A lower cut-off value for younger men (< 59 years old) 17 is required in order avoid risking under diagnosis at an early treatable stage. Data suggest that nearly 20% of prostate cancers are diagnosed in men with values < 4.0 ng/mL, 18 calling for an LoD of < 2.5 ng/mL. 17 First, we established the relationship between the concentration of PSA and the color intensity of PSA on immunochromatography test strips to be linear between 0 and 4 ng/mL PSA (Fig. 3) .
In our study, PSA LoD was > 4.0 ng/mL in serum, with smearing (Fig. 4) . The effect due to the presence or absence of either HSA, IgG and both HSA and IgG from serum samples on the detection of PSA using ICTS is shown clearly (Fig. 5) . Using the developed protocol, the LoD was lowered to 0.5, 1.0 and 2.0 ng/mL in IgG-depleted, HSA/IgG-depleted, and HSAdepleted serum, respectively.
We have developed a very simple method that can be used in public health centers, since only a shaker and microcentrifuge unit are needed, a step towards POCT. Unlike pre-packed commercially available affinity columns, the beads can be easily adjusted to the amount of sample available. This provides reagent economy and little need to recycle the resin, with the benefit of freeing personnel and eliminating potential contamination and health hazards. Moreover, the sample is introduced to the resin without pre-dilution compared with other depletion methods. [2] [3] [4] Also, the depletion of IgG and HSA can be done in a single analytical step, or separately according to an individual's requirements, providing much needed versatility. Our work has shown that the depletion of both IgG and HSA increases the detection sensitivity for HCG and PSA using ICTS. Further, we showed that the depletion of IgG depletion improves sensitivity more than HSA, and that the depletion of both IgG and HSA is less beneficial than that of IgG alone. The differential detection sensitivity is very interesting and, as far as we are aware, the first time to be reported. HSA has been heralded as the protein with the highest potential to interfere/mask the detection of low-abundant markers in blood samples. 19 While this might indeed be the case in some applications, it is possible that the benefit could be higher. Follow-up studies are underway in our laboratory. The lower detection sensitivity in IgG/HSA-depleted samples compared to IgG-depleted samples could in part be due to the role that HSA plays in blocking non-specific adsorption. 20 The absence of HSA (depleted successfully to < 3% 2 and in this study), could have increased non-specific adsorption, thus reducing the potential "optimal" sensitivity of the assay. This highlights the need for detailed studies on high-abundant protein depletion and their individual impact on downstream assays and their applications. 
Conclusion
We have developed an immunoglobulin G (IgG) and human serum albumin (HSA) depletion protocol from serum based on affinity chromatography principles. The method can be applied, without modification, to biomarker and other proteomic studies. We depleted more than 97% of both HSA and IgG separately, and in a single analytical procedure.
The method is reproducible and it substantially lowered the detection limit of PSA, a biomarker for prostate cancer, using POCT immunochromatography test strips (ICTS). Interestingly, the depletion of HSA might not be blankly as beneficial as portrayed in the literature. Our study suggests that it is in fact the depletion of IgG that confers the most benefit.
